Dexcom

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (December 2018) (Learn how and when to remove this message) (Learn how and when to remove this message)

DexCom, Inc.

Company type	Public
Traded as	Nasdaq: DXCM Nasdaq-100 component S&P 500 component
Founded	1999; 25 years ago (1999)
Headquarters	San Diego, California, U.S.
Key people	Kevin Sayer (chairman, president & CEO)
Products	Medical devices
Revenue	US$3.62 billion (2023)
Operating income	US$598 million (2023)
Net income	US$542 million (2023)
Total assets	US$6.26 billion (2023)
Total equity	US$2.07 billion (2023)
Number of employees	c. 9,600 (2023)
Website	dexcom.com
Footnotes / references [1]

DexCom, Inc.^[2] is a company that develops, manufactures, produces, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has manufacturing facilities in Mesa, Arizona and Batu Kawan, Malaysia.